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Pediatric Cardiology
Comparison of Transplacental Treatment of Fetal
Supraventricular Tachyarrhythmias With Digoxin,
Flecainide, and Sotalol
Results of a Nonrandomized Multicenter Study
Edgar T. Jaeggi, MD, FRCPC; Julene S. Carvalho, MD, PhD; Ernestine De Groot, MD; Olus Api, MD;
Sally-Ann B. Clur, MBBCh, MSc, FCP; Lukas Rammeloo, MD; Brian W. McCrindle, MD, FRCPC;
Greg Ryan, MB; Cedric Manlhiot, BSc; Nico A. Blom, MD, PhD
Background—Fetal tachyarrhythmia may result in low cardiac output and death. Consequently, antiarrhythmic treatment
is offered in most affected pregnancies. We compared 3 drugs commonly used to control supraventricular tachycardia
(SVT) and atrial flutter (AF).
Methods and Results—We reviewed 159 consecutive referrals with fetal SVT (n114) and AF (n45). Of these, 75
fetuses with SVT and 36 with AF were treated nonrandomly with transplacental flecainide (n35), sotalol (n52), or
digoxin (n24) as a first-line agent. Prenatal treatment failure was associated with an incessant versus intermittent
arrhythmia pattern (n85; hazard ratio [HR]3.1; P0.001) and, for SVT, with fetal hydrops (n28; HR1.8;
P0.04). Atrial flutter had a lower rate of conversion to sinus rhythm before delivery than SVT (HR2.0; P0.005).
Cardioversion at 5 and 10 days occurred in 50% and 63% of treated SVT cases, respectively, but in only 25% and 41%
of treated AF cases. Sotalol was associated with higher rates of prenatal AF termination than digoxin (HR5.4; P0.05)
or flecainide (HR7.4; P0.03). If incessant AF/SVT persisted to day 5 (n45), median ventricular rates declined
more with flecainide (22%) and digoxin (13%) than with sotalol (5%; P0.001). Flecainide (HR2.1; P0.02)
and digoxin (HR2.9; P0.01) were also associated with a higher rate of conversion of fetal SVT to a normal rhythm
over time. No serious drug-related adverse events were observed, but arrhythmia-related mortality was 5%.
Conclusion—Flecainide and digoxin were superior to sotalol in converting SVT to a normal rhythm and in slowing both
AF and SVT to better-tolerated ventricular rates and therefore might be considered first to treat significant fetal
tachyarrhythmia. (Circulation. 2011;124:1747-1754.)
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Atrial flutter (AF) and paroxysmal supraventriculartachycardia (SVT) are the most common causes of an
abnormally fast fetal heart rate. The vast majority of fetal
SVT is produced by atrioventricular reentrant tachycardia
(AVRT), whereas atrial ectopic tachycardia (AET) and per-
manent junctional reciprocating tachycardia (PJRT) are infre-
quently observed. Although the tachycardia may be well
tolerated, at the more severe end of the spectrum, it may cause
low cardiac output and demise. Fetal hydrops is associated
with a mortality rate as high as 35% compared with 0% to 4%
in nonhydropic fetuses.1 The risk of fetal hydrops increases if
the arrhythmia presents at a younger gestational age and is
rapid, incessant, and enduring, although even intermittent
rhythm disorders may have serious consequences.2,3 Drug
treatment to prevent or treat heart failure is therefore offered
to most mothers who present with frequent or persistent fetal
AF/SVT.
Editorial see p 1703
Clinical Perspective on p 1754
Numerous retrospective studies have demonstrated that
transplacental therapy with digoxin, flecainide, sotalol, or
amiodarone is useful in terminating fetal tachyarrhyth-
mias.4–18 Nonetheless, in the absence of comparative drug
studies, the optimal treatment remains contentious. Digoxin is
the most often used first-line antiarrhythmic drug,5,6,8,9,13,14
albeit its efficacy in controlling fetal SVT within a reasonable
time frame has been questioned.7 Others have suggested that
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flecainide and sotalol are more effective in terminating AF
and SVT4,6–8,12,15; however, rare reports of unexplained fetal
deaths have raised concerns that flecainide and sotalol may
provoke fatal proarrhythmia, although there has been no
objective evidence to support such concerns.4,12
The aim of this retrospective multicenter study was to
compare the safety and efficacy of transplacental digoxin,
flecainide, and sotalol when used as first-line medications to
treat fetal AF/SVT.
Methods
Study Population
We reviewed 159 consecutive cases with a prenatal diagnosis of
AF/SVT at our tertiary care centers between 1998 and 2008. We
excluded cases in which drug therapy had been initiated at another
institution. The study was approved by the research ethics boards.
Patients and Diagnosis
Charts and ultrasound examinations were evaluated for arrhythmia
characteristics, clinical findings, management, and outcome. The
tachycardia was considered incessant if present 50% of the
echocardiographic monitoring time; otherwise, it was classified as
intermittent. Doppler echocardiography and M-mode echocardiogra-
phy were used to distinguish AVRT, AET/PJRT, and AF.19–21 If
applicable, the mechanism was further established by postnatal ECG.
If there was a tachycardia 180 bpm with 1:1 AV conduction and
long-AV/short-VA intervals, AVRT was diagnosed. If the atrial rate
was170 bpm either with 1:1 (AET or PJRT) or variable (AET) AV
conduction and short-AV/long-VA intervals, AET or PJRT was
diagnosed. When the atrial rate exceeded 300 bpm, which was
associated predominantly with 2:1 (range, 1:1 to 4:1) AV conduction
and ventricular response rates between 120 to 350 bpm in this study,
AF was diagnosed. Cases with multiple arrhythmias were classified
according to the dominant mechanism. Fetal hydrops was character-
ized by the presence of at least two of the following findings: ascites,
pleural or pericardial effusions, or skin edema.
Pregnancy Management
The choice of therapy depended on the fetal condition, arrhythmia
characteristics, gestational age, maternal health, and willingness to
undergo treatment. We usually observed brief arrhythmia that was
present 1 to 2 minutes during the echocardiogram without any
therapy. Delivery with postnatal treatment was considered if the
tachycardia was more persistent or early fetal hydrops was docu-
mented after 35 weeks’ gestation. Before 35 weeks, pharmacological
treatment to obtain permanent fetal sinus rhythm was preferred
because the hazard associated with premature delivery was believed
to outweigh the risks of drug therapy. Antiarrhythmics were started
in the hospital to allow serial monitoring of maternal well-being,
serum electrolytes, cardiac rhythm, and ECG. Fetal well-being was
monitored by frequent biophysical profile scoring, as well as
Doppler and ultrasound examinations, until cardioversion or near-
normal heart rate control was achieved.
Prenatal treatment was not randomized, but varied among study
centers (Table 1). Primary choices were sotalol in institution 1,
digoxin or flecainide in institution 2, and flecainide in institution 3,
which were used in 87%, 87%, and 89% of treated cases, respec-
tively. Sotalol was usually given twice daily at a median dose of 160
(range, 80–320 mg/d), and the dosage was increased within a few
days if the SVT/AF remained unresponsive to a maximum dose of
480 mg/d. The starting dose of sotalol for fetal hydrops was 320
mg/d. The daily dosage of flecainide was 300 mg/d (range, 200–450
mg/d) in 3 doses, and if applicable, this was adjusted to obtain
therapeutic drug levels between 0.2 and 1 g/mL. The oral loading
dose of digoxin was 1.5 to 2 mg over 2 days, followed by
maintenance dosages between 0.375 and 1 mg/d, aiming to obtain
maternal drug levels in the upper therapeutic range between 2 and
2.5 ng/mL.
Definitions and Outcome Measures
Analyses were based on the initial treatment intent to avoid the
effects of crossover therapy. Patients started with a monotherapy of
sotalol, flecainide, or digoxin were assigned to their respective drug
cohort. If digoxin was started simultaneously with sotalol or flecain-
ide, which was the case in 7% of SVT and 8% of AF patients, these
patients were included in the sotalol or flecainide cohorts. Changes
in first-line prenatal management such as the addition of other drugs
and delivery were also analyzed. Primary outcome measures were
the time interval from treatment initiation to permanent cardiover-
sion and, once established, the freedom from arrhythmia recurrence
from the time of conversion until birth on maintenance treatment.
Only the final outcome was considered to classify cases; fetuses with
a recurrence who eventually achieved permanent sinus rhythm were
counted as a treatment success but only after the final cardioversion.
Intrauterine demise and delivery for tachyarrhythmia were consid-
ered treatment failures. Any recurrence of fetal SVT/AF after
documentation of a completely normal cardiac rhythm by echocar-
diography was classified as maintenance treatment failure. Postnatal
outcome was characterized as self-limiting (resolution of the
tachycardia and no need for drug treatment within a year of birth),
controlled (no tachycardia on treatment), or drug refractory (incom-
plete control despite drug treatment).
Statistics
Data are presented as meanSD, median with minimal and maximal
values, frequency, hazard ratio (HR), and 95% confidence interval
(CI) as appropriate. Differences between cohorts were estimated
with the 2 test and ANOVA or nonparametric Kruskal-Wallis
ANOVA as appropriate. Time to permanent cardioversion was
assessed by Kaplan-Meier estimates with Cox proportional hazard
model for group comparisons (PHREG on the SAS system). Multi-
variable survival regression models were created to test whether
treatment effect was independent of important covariates known or
hypothesized to be associated with the probability of conversion to
sinus rhythm. Analyses were performed with SAS Statistical Soft-
ware version 9.2 (SAS Institute, Inc, Cary NC) and Prism 5
(GraphPad Software, San Diego, CA).
Results
Fetal Tachycardia Presentation
Table 2 shows the characteristics of the AF and SVT cohorts.
Of 159 referrals, 45 had AF and 114 had SVT; AVRT was the
main cause of fetal hydrops (34 of 41, 83%). Compared with
Table 1. Institutional Differences in Their Choice of First-Line Fetal Antiarrhythmic Therapy
Total Institution 1 Institution 2 Institution 3 P
Proportion treated, n (%) 111/159 (70) 55/63 (87) 38/64 (59) 18/32 (56) 0.001
First-choice drug, n (%) 0.001
Digoxin 24 5 (9) 17 (45) 2 (11)
Flecainide 35 3 (5) 16 (42) 16 (89)
Sotalol 52 47 (87) 5 (13) 0 (0)
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well-tolerated AVRT, fetal hydrops was associated with an
incessant arrhythmia pattern (91% versus 47%; P0.001)
and faster heart rates (25326 versus 23933 bpm; P0.01)
independently of gestational age. On average, AF was diag-
nosed 4 weeks later than SVT (P0.001) with slower
ventricular rates (P0.001), whereas fetal hydrops was less
common (P0.03). Hydropic fetuses with AF were younger
than those presenting without hydrops (30.22.6 versus
343.3 weeks; P0.008), whereas tachycardia rates
(P0.77) and patterns (P0.57) did not differ. Finally,
AET/PJRT cases had the slowest rates of tachycardia
(20018 bpm; P0.001) and were the least likely to be
hydropic (1 of 16, 6%).
Overall, 9 fetuses (6%) also had structural heart disease.
These included 3 AF cases, 1 each with left isomerism, aortic
stenosis, and coarctation of the aorta. Of 6 SVT cases, 2 had
cardiac tumors, 2 had ventricular septal defects, 1 had Ebstein
anomaly, and 1 had left heart hypoplasia.
Prenatal Management Characteristics
Tables 3 and 4 compare treated and untreated cohorts with AF
and SVT. Treated fetuses were younger and more likely to be
hydropic, whereas cohorts treated with digoxin, flecainide, or
sotalol were largely comparable in clinical presentation,
treatment duration, and outcome. Overall, 80% of AF cases
(36 of 45) and 66% of SVT fetuses (75 of 98) received sotalol
(n52), flecainide (n35), or digoxin (n24).
Changes from first-line therapy over time were comparable
among arrhythmias and drugs (Figure 1). Treatment modifi-
cations were rare during the initial 5 days of therapy, but by
Table 2. Characteristics of 159 Cases With Fetal Atrial Flutter or Supraventricular Tachycardia
Total Institution 1 Institution 2 Institution 3 P
Total fetuses, n 159 63 64 32 1 vs 2 vs 3
Fetuses with AF, n (%) 45/159 (28) 20/63 (32) 14/64 (22) 11/32 (34) 0.32
Age at diagnosis, wk 33.23.5 33.62.8 33.64 31.84.1 0.43
Heart rate, bpm 22337 21617 21041 25047 0.08
Incessant arrhythmia, n (%) 38 (84) 19 (95) 11 (79) 8 (73) 0.20
Fetal hydrops, n (%) 6 (13) 1 (5) 1 (7) 4 (36) 0.04
Prenatally treated cases, n (%) 36 (80) 18 (90) 10 (71) 8 (73) 0.32
Fetuses with SVT, n (%) 114/159 (72) 43/63 (68) 50/64 (78) 21/32 (66) 0.32
SVT mechanism, n (%) 0.63
AVRT 98 (86) 36 (84) 45 (90) 17 (81)
AET 14 (12) 6 (14) 5 (10) 3 (14)
PJRT 2 (2) 1 (2) 0 (0) 1 (5)
Age at diagnosis, wk 29.16 27.85.6 30.75.6 28.27.1 0.05
Heart rate, bpm 24235 24727 24840 22029 0.003
Incessant arrhythmia, n (%) 69 (61) 31 (72) 26 (52) 12 (57) 0.13
Fetal hydrops, n (%) 35 (31) 17 (40) 15 (30) 3 (14) 0.12
Prenatally treated cases, n (%) 75 (66) 37 (86) 28 (56) 10 (48) 0.001
AF indicates atrial flutter; SVT, supraventricular tachycardia; AVRT, atrioventricular reentrant tachycardia; AET, atrial ectopic
tachycardia; and PJRT, permanent reciprocating junctional tachycardia.
Table 3. Pregnancy Management and Outcome of 45 Fetuses With Atrial Flutter
Fetal Therapy
P
First-Line Treatment (n36)
PNo Yes Sotalol Flecainide Digoxin
Fetuses, n (%) 9 (20) 36 (80) 17 (47) 9 (25) 10 (28)
Age at diagnosis, wk 36.13.1 32.43.3 0.003 32.72.5 31.24.4 32.83.4 0.48
Heart rate, bpm 22461 22527 0.50 21617 24733 22224 0.01
Incessant arrhythmia, n (%) 6 (67) 32 (89) 0.37 17 (100) 7 (78) 8 (80) 0.13
Fetal hydrops, n (%) 1 (11) 5 (14) 1.00 2 (12) 2 (22) 1 (10) 0.71
Time from diagnosis to
delivery, d
1 (0–60) 28 (2–98) 0.002 28 (7–71) 29 (5–77) 26 (2–98) 0.88
Treatment duration, d NA 28 (2–98) 28 (7–71) 28 (4–73) 23 (2–98) 0.83
Fetal demise, n (%) 0 (0) 1 (3) 1.00 0 1 0 0.21
Postnatal demise, n (%) 2 (22) 0 (0) 0.04 0 0 0 1.00
Age at delivery, wk 37.22.3 37.32.5 1.00 37.42.7 36.73.1 37.61.7 0.70
Birth weight, kg 3.40.4 3.30.6 0.56 3.00.6 3.60.6 3.50.4 0.04
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day 10, one third of mothers had received a second antiar-
rhythmic drug or had been delivered. Overall, 13 of 24
women (54%) treated with digoxin received another medica-
tion (5 sotalol, 7 flecainide) or had been delivered (n1) at a
median of 6 treatment days (range, 3–33 days). Of 35
flecainide-treated cases, 14 (40%) ended up with modified
management (9 digoxin, 2 sotalol, 1 amiodarone, 2 deliveries)
at 9 treatment days (range, 2–15 days). Of 52 sotalol-treated
cases, 26 (50%) required modified management (17 digoxin,
7 flecainide, 2 deliveries) at 7 treatment days (range, 2–15
days). Finally, 3 hydropic fetuses with therapy-resistant
AVRT on oral flecainide/digoxin converted to sinus rhythm
after direct fetal administration of adenosine and amiodarone
or digoxin as third-line agents.
Because AF was diagnosed later, the duration of fetal
therapy was shorter (P0.001) and delivery by caesarean
section more likely than with SVT (55% versus 32%;
P0.03). Figure 2 compares the cardioversion rates of SVT
and AF during the first month of treatment. Atrial flutter
responded more slowly to drug therapy (HR2; 95%
CI1.2–3.3; P0.005); rhythm control at 5 and 10 days was
achieved in 50% and 63% of fetuses with SVT but in only
25% and 41% of similarly managed fetuses with AF. The rate
of treatment failure was higher if SVT (HR2.6; 95%
CI2.0–8.9; P0.001) and AF (HR4.9; 95% CI4.3–
311.8; P0.001) were incessant and if SVT was associated
with fetal hydrops (HR1.8; 95% CI1.0–3.1; P0.04) at
the time of diagnosis (Figures 3 and 4). It took more than
twice as long (9 versus 4 days) for conversion of 50% of SVT
cases to a normal rhythm if fetuses were hydropic.
First- and Second-Line Therapy
Estimates of treatment-resistant tachyarrhythmia with first-
line digoxin, flecainide, and sotalol are shown in Figure 5.
For patients with fetal SVT, in multivariable models adjusted
for hydrops and arrhythmia pattern and including both first-
and second-line therapy in the same model, the use of digoxin
(HR2.9; 95% CI1.3– 6.5; P0.01) or flecainide
(HR2.1; 95% CI1.3–3.8; P0.02) as first-line therapy
was associated with a higher rate of arrhythmia termination
compared with sotalol (Figure 5A). None of these agents as
second-line therapy were associated with a greater rate of
arrhythmia termination. Five days after treatment was begun,
59% of flecainide-treated and 57% of digoxin-treated SVT
cases but only 38% of sotalol-treated cases were in normal
rhythm. The median time to conversion of SVT cases was 3
days with digoxin, 4 days with flecainide, and 12 days with
sotalol.
For patients with AF, in multivariable models adjusted for
incessant versus intermittent arrhythmia pattern and including
first- and second-line therapy in the same model, first-line
Figure 2. Freedom from prenatal conversion of atrial flutter (AF)
vs supraventricular tachycardia (SVT) to persistent sinus rhythm
despite transplacental antiarrhythmic therapy.
Table 4. Pregnancy Management and Outcome of 114 Fetuses With Supraventricular Tachycardia
Fetal Therapy
P
First-Line Treatment (n75)
PNo Yes Sotalol Flecainide Digoxin
Fetuses, n (%) 39 (34) 75 (66) 35 (48) 26 (35) 14 (19)
Age at diagnosis, wk 31.96.5 27.75.2 0.001 27.35.5 275.5 30.23.6 0.15
Heart rate, bpm 23551 24829 0.16 24628 25230 24529 0.64
Incessant arrhythmia, n (%) 16 (41) 53 (71) 0.003 27 (77) 18 (69) 8 (57) 1.97
Fetal hydrops, n (%) 7 (18) 28 (37) 0.036 15 (43) 10 (38) 3 (21) 1.98
Time from diagnosis to
delivery, d
28 (0–169) 65 (1–181) 0.006 66 (1–140) 75 (4–181) 50 (12–143) 0.32
Treatment duration, d 65 (1–158) 64 (1–140) 72 (2–158) 50 (12–143) 0.41
Fetal demise, n (%) 0 (0) 4 (5) 0.30 2 2 0 1.08
Postnatal demise, n (%) 3 (8) 2 (3) 0.34 1 0 1 1.79
Age at delivery, wk 38.92.2 382.5 0.07 37.82.2 38.22.5 37.83.1 0.78
Birth weight, kg 3.60.6 3.20.6 0.001 3.10.6 3.30.6 3.00.6 0.30
Figure 1. Freedom from changes in first-line treatment of fetal
atrial flutter (AF) and supraventricular tachycardia (SVT).
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sotalol was associated with a higher rate of arrhythmia
termination compared with digoxin (HR5.4; 95% CI1.0–
30.0; P0.05) or flecainide (HR7.4; 95% CI1.2–46.1;
P0.03; Figure 5B). The same observation was made with
the second-line therapy, although it did not reach statistical
significance because of too few cases (P0.11 for sotalol
versus digoxin; P0.13 for sotalol versus flecainide). At day
5 of treatment, only 13% of fetuses on flecainide, 21% on
digoxin, and 29% on sotalol had a normal heart rhythm. The
median time to conversion of AF cases was 12 days with
sotalol, whereas this was not achieved with digoxin or
flecainide before delivery. Nonetheless, when incessant SVT
(n23) or AF (n22) persisted to day 5 of treatment,
ventricular rates were lowered more significantly with fle-
cainide (median, 22%) and digoxin (13%) than with
sotalol (5%; P0.001; Figure 6).
Maintenance Therapy and Outcome
Maintenance treatment failure was uncommon (Figure 7).
Fetal hydrops resolved in the majority (76%) of treated cases
before delivery. Most babies, treated and untreated, were born
near term with normal birth weights. Only 9 of the 159
fetuses with arrhythmia (6%) were delivered at 35 weeks’
gestation. Neonatal arrhythmia was more common in fetuses
who had been untreated than in those who were treated (44%
versus 24%; P0.02) and was documented in 46% of AF
cases, 21% of AVRT cases, and 31% of AET/PJRT cases.
Atrial flutter did not recur after postnatal cardioversion either
with (11%) or without (89%) prophylactic antiarrhythmic
therapy. Finally, of 106 survivors with SVT, 11 (10%) with
only brief periods of SVT were lost to follow-up, whereas 62
had self-limiting, 29 had drug-controlled, and 4 had drug-re-
sistant SVT (1 AET, 1 PJRT, 2 AVRT) during their first year
of life.
Morbidity and Mortality
Arrhythmia-related mortality of nonhydropic and hydropic
cases was 0% (0 of 118; 95% CI0–3) and 17% (7 of 41;
95% CI9–31), respectively (P0.001). The first hydropic
fetus succumbed within a day after transplacental digoxin/
sotalol and direct fetal adenosine were given for incessant
AVRT at 30 weeks. Three other fetuses, 2 with AVRT and 1
with AF, failed to respond to sotalol (n1), flecainide (n2),
and second-line medication and died between 6 and 42 days
Figure 3. Freedom from prenatal termination of incessant vs
intermittent supraventricular tachycardia and atrial flutter to anti-
arrhythmic treatment.
Figure 4. Freedom from prenatal termination of supraventricular
tachycardia to antiarrhythmic treatment in fetuses with vs with-
out hydrops.
Figure 5. A, Freedom from prenatal termination of supraventric-
ular tachycardia (A; n75) and atrial flutter (B; n36) over time
with digoxin (D), flecainide (F), and sotalol (S).
Figure 6. Percentage changes in fetal ventricular rate if inces-
sant atrial flutter (n22) and supraventricular tachycardia (n23)
persisted after 5 days of digoxin (n9), flecainide (n14), and
sotalol (n22) administration.
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after initiation of therapy. The fifth case with AVRT had
sudden onset of severe bradycardia before any prenatal
treatment could be started and died during delivery by
emergency caesarian section at 25 weeks. The sixth case with
AVRT refractory to both digoxin and flecainide for 3 weeks
died of multiorgan failure after delivery at 32 weeks. The
final case had incessant AF and was delivered at 32 weeks
after the mother went into spontaneous labor. The newborn
developed broad-complex tachycardia at 2 days of age and
could not be resuscitated. Five additional deaths occurred as
a result of non–arrhythmia-related causes: 1 was a stillbirth
with umbilical cord strangulation, and 4 babies received
palliative care for perinatal asphyxia (n1), cardiac tumors
(n2), or glutaric aciduria type 2 with dilated cardiomyopa-
thy and encephalopathy (n1).
Two fetuses (1.2%) who were delivered prematurely had
therapy-resistant SVT and developed post-hemorrhagic hy-
drocephalus suggestive of arrhythmia-related insults. One
needed ventriculoperitoneal shunt drainage, but neither had
any developmental sequelae.
One third of mothers reported adverse symptoms that were
probably drug related. Their main complaints were nausea
and dizziness attributed to the use of digoxin (38%), flecain-
ide (20%), or sotalol (10%) and visual disturbances with
flecainide (14%). In most cases, these symptoms were minor,
so no treatment change was required, except for 3 women. In
the first, flecainide/digoxin was stopped for 3 days because of
low serum magnesium and potassium levels. The second
mother became bradycardic on a low dose of sotalol (120
mg/d). On day 25 of treatment, she felt dizzy with a heart rate
of 40 bpm. A healthy male baby was delivered the same day
at 37 weeks 4 days, and the maternal symptoms resolved. In
the third pregnancy, incessant AVRT with severe fetal
hydrops could be terminated only with maximal dosages of
flecainide (400 mg/d) and sotalol (480 mg/d). This was well
tolerated by the mother, but the fetal heart rate decreased to
110 bpm after successful cardioversion. The fetal heart rate
normalized after reduction of sotalol to 320 mg/d.
Discussion
This study is the first to establish response-rate curves over
time for treatment with digoxin, flecainide, and sotalol. Our
multicenter experience shows that the fetal response to
transplacental therapy was associated with the fetal state, the
type of tachycardia, and the choice of antiarrhythmic. Su-
praventricular tachycardia was significantly better controlled
by transplacental medication than AF, whereas fetal hydrops
and incessant SVT/AF were independently associated with
slower cardioversion rates. Sotalol was associated with the
highest rate of prenatal AF termination. On the contrary,
flecainide and digoxin were associated with superior conver-
sion rates of SVT to a normal rhythm and greater slowing to
better-tolerated ventricular rates of persistent AF and SVT
than sotalol.
Fetal State
In the absence of fetal hydrops, arrhythmia-related mortality
in this study was 0%, suggesting that transplacental antiar-
rhythmic therapy is safe and effective regardless of the drug
chosen. In hydropic fetuses, however, the rate of arrhythmia-
mediated death was 17%, which is comparable to most other
reported rates.6,8,12 Fetal hydrops was strongly associated
with incessant AVRT; overall, one third of all AVRT fetuses
were hydropic compared with 6% with AET/PJRT and 13%
with AF. Therefore, rapid cardioversion to sinus rhythm
appears to be most pressing for incessant AVRT. Unfortu-
nately, fetal hydrops itself is associated with treatment
failure,6–8,18 as we confirmed. For digoxin, this has been
explained by incomplete passage of the drug across the
placenta, so adequate fetal levels are not obtained despite
often near-toxic maternal dosages.22 Flecainide and sotalol,
on the other hand, continue to cross the placenta readily even
if there is fetal hydrops and thus should be preferred for
patients in heart failure.4,14,16,23 In this study, hydropic fetuses
with SVT responded in general more slowly than nonhy-
dropic fetuses, regardless of the choice of medication. Be-
cause fetal drug levels were not obtained, it is unclear
whether this was due to impaired drug transfer/distribution,
changes in electrophysiological properties, eg, resulting from
tissue edema, or both. In our series, arrhythmia-related
demise occurred predominantly after a lengthy period of
unsuccessful treatment in a severely hydropic fetus. These
“late” deaths may be preventable with more effective drug
choices.
Arrhythmia Type
Previous studies, summarized by Krapp et al,18 reported
comparable prenatal success rates in terminating AF and SVT
with digoxin, but response times were usually not evaluated.
We found that, although prenatal rhythm control was even-
tually obtained in a significant proportion of chronically
treated fetuses, the response of AF to transplacental therapy
differed substantially from other forms of SVT. This should
not be surprising because SVT and AF have diverse causes.
Cardioversion of AF requires an antiarrhythmic drug to
terminate the atrial reentrant circuit. This was achieved in
only half of our treated AF cases within the first 2 weeks and
in two thirds before delivery. Despite the rather low success
rate, arrhythmia-related mortality was relatively low, proba-
bly because AF develops predominantly late in gestation and,
even in persistent AF, near-normal ventricular rates may be
obtained by the pharmacological delay of myocardial/AV
nodal conduction. Because AVRT and PJRT involve atrial
and ventricular myocardial tissue and conduction through the
Figure 7. Freedom from prenatal recurrence of atrial flutter (AF)
vs supraventricular tachycardia (SVT) on antiarrhythmic mainte-
nance therapy.
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AV node and accessory pathway, termination of these ar-
rhythmias is possible by the electrophysiological alteration of
one or several tissues. Suppression of enhanced atrial focal
automaticity is needed to terminate AET. Treatment of
AET/PJRT may occasionally be challenging,20 although we
did not find them to be associated with an increased risk of
treatment failure with the limitation that both disorders are
rare and our numbers were likely too small to detect differ-
ences from AVRT (data not shown). Compared with AF, fetal
SVT responded faster and more consistently to pharmacolog-
ical treatment, whereas both AF and SVT had an 8% to 15%
recurrence rate on maintenance treatment. We would there-
fore recommend at least weekly assessment of the fetal heart
rate until delivery once the arrhythmia appears to be
controlled.
First-Line Medication
Extensive data from smaller studies exist on the success of fetal
therapy with specific antiarrhythmic drugs. A summary of these
data was recently published.24 When these drugs were used as
first choice, termination of AF/SVT before birth occurred in
51% of fetuses (115 of 226) with digoxin,6–9,13,14,19,20,25 in 64%
(45 of 70) with flecainide,4,6–8,16 and in 66% (23 of 35) with
sotalol.10,12,15,19 This implies that sotalol and flecainide may be
the most effective drugs regardless of the underlying arrhyth-
mia mechanism. Nevertheless, clinically more relevant than
rates of arrhythmia termination at birth is the response time to
a particular intervention, and this information is available
only for digoxin in 1 study.26 Our numbers are too small to
detect meaningful differences in survival among drug co-
horts. Nonetheless, because the risk of demise increases once
the fetus is in heart failure, rapid restoration of a normal fetal
heart rate is imperative. Two drug effects may be useful in
improving fetal hemodynamics: reduction of heart rate to one
that is better tolerated and, ideally, cardioversion to a normal
rhythm. Our study shows that both transplacental flecainide
and digoxin were associated with higher rates of conversion
of SVT to a normal rhythm and with greater slowing of
persistent tachycardia than sotalol. Flecainide has previously
been reported to result in a significant reduction in SVT
rate.14 We found that flecainide and digoxin were similarly
effective in reducing AF and SVT rates. Sotalol, on the other
hand, was associated with a higher rate in terminating fetal
AF, but it had only modest effects on tachycardia rates. This
implies that in the future we might combine sotalol with
either digoxin or flecainide as first-line therapy if AF control
is a matter of urgency because these combinations give the
best chance of terminating fetal AF or of reducing ventricular
rates in persistent AF. The safety and efficacy of combined
drug treatment need to be evaluated in a larger prospective
study.
Study Limitations
Several limitations are acknowledged. This is a retrospective
review, and pregnancy management was not randomized but
depended on institutional preferences. This explains the
higher proportion of fetuses treated in institution 1. Caesarean
section rates vary between centers and populations; hence,
this was not evaluated separately as an outcome variable. We
defined treatment as being successful if SVT/AF was termi-
nated because it was not possible to objectively estimate a
reduction in arrhythmia duration over time from stored
recordings. Finally, unlike flecainide and digoxin, sotalol
levels were not monitored because sotalol does not have the
same narrow margin between therapeutic and toxic serum
levels. This means that, in the absence of fetal hydrops,
sotalol was usually started at the lowest dosage considered to
be therapeutic (160 mg/d) and then increased until the desired
effect was obtained. This may, in part, explain delayed
treatment effects compared with flecainide and digoxin.
Conclusions
We found significant differences in the fetal response to
pharmacological treatment between SVT and AF. Our results
may be useful in improving our understanding of the poten-
tials and limitations of antiarrhythmic drug therapy and, in
persistent AF or SVT, helping to define a treatment period
after which an alternative management should be considered.
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CLINICAL PERSPECTIVE
Fetal atrial flutter and supraventricular tachycardia may result in low cardiac output and death. Consequently, maternal
antiarrhythmic treatment is offered in most affected pregnancies. This retrospective multicenter study is the first to compare
the efficacy and safety of transplacental digoxin, flecainide, and sotalol, the most commonly used drugs to treat fetal
tachyarrhythmia. In the absence of fetal hydrops, arrhythmia-related mortality was 0%, suggesting that transplacental
antiarrhythmic therapy is safe and effective regardless of the drug chosen. In fetal hydrops, however, when rapid heart rate
control becomes a matter of urgency to improve the chances of survival, the rate of arrhythmia-mediated death was 17%.
We found that the fetal response to drug therapy was significantly associated with the type of tachycardia, fetal state, and
choice of antiarrhythmic. Atrial flutter, fetal hydrops, and an incessant arrhythmia pattern were independently associated
with slower cardioversion rates. Flecainide and digoxin were associated with increased likelihood of conversion of fetal
supraventricular tachycardia to a normal rhythm and significantly greater slowing of ventricular rates of persistent atrial
flutter/supraventricular tachycardia than sotalol. The highest rate of prenatal atrial flutter termination was observed with
sotalol, albeit this was achieved in only about half of the sotalol-treated patients. Flecainide or digoxin might therefore be
considered first to treat significant fetal tachyarrhythmia, perhaps in combination with sotalol to treat poorly tolerated atrial
flutter. Our results may also be useful in improving our understanding of the potentials and limitations of antiarrhythmic
drug therapy and, in persistent arrhythmia, helping to define a treatment period after which an alternative management
should be considered.
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